DISCORDANT XENOGRAFTING
DISCORDANT XENOGRAFTING
批准号:
2223218
负责人:
FRITZ H BACH
金额:
$13.25万
依托单位国家:
美国
项目类别:
财政年份:
1991
资助国家:
美国
项目状态:
已结题
起止时间:
1991-08-01 至 1995-07-31
关键词:
antigen antibody reaction complement pathway guinea pigs heart circulation heart transplantation histocompatibility immunopathology immunosuppressive in situ hybridization isoantibody laboratory rat newborn animals nucleic acid probes reptile poison thrombosis tissue donors vascular endothelium xenotransplantation
中文摘要
在符合以下条件的物种之间进行立即血管化器官移植
在系统发育上相距甚远的,称为不协调种
联合,导致超急性排斥反应。论超急性发作的基础
排斥反应可能涉及(I)结合受体的天然抗体
对供体血管内皮细胞,(Ii)随后被激活的补体
与天然抗体结合或通过替代途径结合,以及(Iii)
供体器官内皮细胞的激活导致
血管内血栓形成。超急性排斥反应的情况包括
血管内皮细胞激活的常见后果是什么:
细胞渗入血管外间隙,浮肿,沉积
内皮上的粒细胞和血小板与血栓形成。
超急性排斥反应可以在短短15分钟内发生,但通常
在2小时内完成,在某种程度上取决于不和谐
研究了物种组合。过去的研究在大多数情况下都试图
部分,干扰三个相关领域中的一个或另一个
如上所述的超急性排斥反应。我们的假设是为了避免
超急性排斥将有必要干扰几个
排斥反应过程的发病特点。尤其重要的是,
我们认为,仔细评估干预措施可能会防止
血管内皮细胞激活或干扰其后果。我们
然而,相信这样的干预必须在动物身上尝试
哪些天然抗体作用和补体作用受到了损害
尽最大可能。这样的实验在这里被提出。
我们将把豚鼠心脏移植到大鼠身上(在非常罕见的情况下,我们
应使用新生微型猪心脏作为捐赠器官)。我们计划耗尽
天然抗体,并试图保持极低水平的这种
抗体主要通过使用免疫抑制药定向
产生天然抗体的B细胞。我们应该用眼镜蛇的毒液
消除替代性和经典性补体作用的因素
小路。它的背景是耗尽的天然抗体和
妥协的补充,我们将测试各种干预处理
伴随着内皮细胞的激活或激活的后果。后
对不同治疗方案的单独评估,我们计划联合
治疗策略在很大程度上基于免疫病理学
拒绝心,我们希望从这些研究中了解到哪些策略是
在试图避免超急性排斥反应方面真正起到补充作用。
英文摘要
Transplantation of immediately vascularized organs between species that are
phylogenetically widely separated, referred to as discordant species
combinations, results in hyperacute rejection. The basis of hyperacute
rejection likely involves (i) natural antibodies of the recipient that bind
to donor vascular endothelium, (ii) complement that is activated consequent
to natural antibody binding or via the alternative pathway, and (iii)
activation of endothelial cells of the donor organ resulting in
intravascular thrombosis. The picture of hyperacute rejection includes
what are the commonly accepted consequences of endothelial activation:
extravasation of cells into the extravascular space, edema, deposition of
granulocytes and platelets on the endothelium and thrombosis.
Hyperacute rejection can occur in as little as 15 minutes but is usually
completed within 2 hours, depending in some measure on the discordant
species combination studied. Past studies have attempted, for the most
part, to interfere with one or the other of the three areas related to
hyperacute rejection as outlined above. It is our hypothesis that to avert
hyperacute rejection it will be necessary to interfere with several of the
pathogenetic features of the rejection process. Especially important, to
our mind, is the careful evaluation of interventions that may prevent
endothelial cell activation or interfere in the consequences thereof. We
believe, however, that such interventions must be attempted in animals in
which natural antibody action and complement action have been compromised
to the extent possible. Such experiments are proposed herein.
We shall transplant guinea pig hearts to rats (n very rare instances, we
shall use newborn micropig hearts as the donor organ). We plan to deplete
natural antibodies and attempt to maintain very low levels of such
antibodies primarily through the use of immunosuppressive agents directed
at the B cells producing the natural antibodies. We shall use cobra venom
factor to abrogate complement action of both the alternative and classical
pathways. It is on a background of depleted natural antibodies and
compromised complement that we shall test various interventions dealing
with endothelial cell activation or the aftermath of activation. After the
evaluation of various treatment protocols individually, we plan to combine
therapeutic strategies based largely on the immunopathology of the
rejecting hearts, from which studies we hope to learn which strategies are
truly complementary in attempts to avert hyperacute rejection.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Depletion of IgM xenoreactive natural antibodies by injection of anti-mu monoclonal antibodies.
通过注射抗 mu 单克隆抗体消除 IgM 异种反应性天然抗体。
DOI:
10.1111/j.1600-065x.1994.tb00874.x
发表时间:
1994
期刊:
Immunological reviews
影响因子:
8.7
作者:
[Latinne,D, Soares,M, Havaux,X, Cormont,F, Lesnikoski,B, Bach,FH, Bazin,H]
通讯作者:
Bazin,H
Anti-B cell agents: suppression of natural antibodies and prolongation of survival in discordant xenografts.
抗 B 细胞制剂:抑制天然抗体并延长不一致异种移植物的存活时间。
DOI:
--
发表时间:
1994
期刊:
Transplantation proceedings
影响因子:
0.9
作者:
[Blakely,ML, VanderWerf,WJ, Dalmasso,AP, Bach,FH]
通讯作者:
Bach,FH
Retinoic acid inhibits expression of E-selectin in endothelial cells and prolongs discordant xenograft survival.
视黄酸抑制内皮细胞中 E-选择素的表达并延长异种移植物的存活时间。
DOI:
--
发表时间:
1994
期刊:
Transplantation proceedings
影响因子:
0.9
作者:
[Blakely,ML, VanderWerf,WJ, Stuhlmeier,K, Dalmasso,AP, Winkler,H, Bach,FH]
通讯作者:
Bach,FH
DOI:
10.1097/00007890-199411000-00001
发表时间:
1994-11
期刊:
Transplantation
影响因子:
6.2
作者:
[M. Blakely;W. J. van der Werf;M. Berndt;A. Dalmasso;F. Bach;W. Hancock]
通讯作者:
M. Blakely;W. J. van der Werf;M. Berndt;A. Dalmasso;F. Bach;W. Hancock
Endothelial and host mononuclear cell activation and cytokine expression during rejection of pig-to-baboon discordant xenografts.
猪与狒狒不一致的异种移植物排斥过程中内皮细胞和宿主单核细胞的激活和细胞因子的表达。
DOI:
--
发表时间:
1995
期刊:
Transplantation proceedings.
影响因子:
--
作者:
[Lesnikoski,BA, Shaffer,DA, VanderWerf,WJ, Dalmasso,AP, Soares,MP, Latinne,D, Bazin,H, Hancock,WW, Bach,FH]
通讯作者:
Bach,FH
共 12 条
Heme Oxygenase-1: protection against chronic rejection
-
批准号:7538400
-
项目类别:
-
资助金额:$41.27万
-
财政年份:2006
-
负责人:FRITZ H BACH
-
依托单位:
Heme Oxygenase-1: protection against chronic rejection
-
批准号:7166066
-
项目类别:
-
资助金额:$41.27万
-
财政年份:2006
-
负责人:FRITZ H BACH
-
依托单位:
Heme Oxygenase-1: protection against chronic rejection
-
批准号:7327813
-
项目类别:
-
资助金额:$41.27万
-
财政年份:2006
-
负责人:FRITZ H BACH
-
依托单位:
Heme Oxygenase-1: protection against chronic rejection
-
批准号:7035144
-
项目类别:
-
资助金额:$42.5万
-
财政年份:2006
-
负责人:FRITZ H BACH
-
依托单位:
Heme Oxygenase 2005 -- the 4th International Conference
-
批准号:7001754
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2005
-
负责人:FRITZ H BACH
-
依托单位:
Regulation of Endothleial Cell Apoptosis by HO-1 and CO
-
批准号:6638740
-
项目类别:
-
资助金额:$29.75万
-
财政年份:2001
-
负责人:FRITZ H BACH
-
依托单位:
Regulation of Endothleial Cell Apoptosis by HO-1 and CO
-
批准号:6745108
-
项目类别:
-
资助金额:$29.75万
-
财政年份:2001
-
负责人:FRITZ H BACH
-
依托单位:
XENOTRANSPLANT--GENETICALLY ENGINEERED ENDOTHELIAL CELLS
-
批准号:6184287
-
项目类别:
-
资助金额:$32.71万
-
财政年份:1998
-
负责人:FRITZ H BACH
-
依托单位:
XENOTRANSPLANT--GENETICALLY ENGINEERED ENDOTHELIAL CELLS
-
批准号:6389716
-
项目类别:
-
资助金额:$33.42万
-
财政年份:1998
-
负责人:FRITZ H BACH
-
依托单位:
XENOTRANSPLANT--GENETICALLY ENGINEERED ENDOTHELIAL CELLS
-
批准号:2637613
-
项目类别:
-
资助金额:$31.37万
-
财政年份:1998
-
负责人:FRITZ H BACH
-
依托单位:
XENOTRANSPLANT--GENETICALLY ENGINEERED ENDOTHELIAL CELLS
-
批准号:6056438
-
项目类别:
-
资助金额:$32.03万
-
财政年份:1998
-
负责人:FRITZ H BACH
-
依托单位:
MOLECULAR STUDIES OF NK CELLS AND NK/LAK FUNCTION
-
批准号:3128427
-
项目类别:
-
资助金额:$17.83万
-
财政年份:1992
-
负责人:FRITZ H BACH
-
依托单位:
MOLECULAR STUDIES OF NK CELLS AND NK/LAK FUNCTION
-
批准号:2060837
-
项目类别:
-
资助金额:$31.57万
-
财政年份:1992
-
负责人:FRITZ H BACH
-
依托单位:
DISCORDANT XENOGRAFTING
-
批准号:3365969
-
项目类别:
-
资助金额:$9.73万
-
财政年份:1991
-
负责人:FRITZ H BACH
-
依托单位:
DISCORDANT XENOGRAFTING
-
批准号:3365970
-
项目类别:
-
资助金额:$11.8万
-
财政年份:1991
-
负责人:FRITZ H BACH
-
依托单位:
ESTABLISHMENT OF UPGRADED FLOW CYTOMETRY SYSTEM CORE
-
批准号:3520383
-
项目类别:
-
资助金额:$31.5万
-
财政年份:1988
-
负责人:FRITZ H BACH
-
依托单位:
STUDIES OF HLA CLASS II GENES
-
批准号:3134132
-
项目类别:
-
资助金额:$28.81万
-
财政年份:1985
-
负责人:FRITZ H BACH
-
依托单位:
STUDIES OF HLA CLASS II GENES
-
批准号:3134131
-
项目类别:
-
资助金额:$27.47万
-
财政年份:1985
-
负责人:FRITZ H BACH
-
依托单位:
STUDIES OF HLA CLASS II GENES
-
批准号:3134129
-
项目类别:
-
资助金额:$22.84万
-
财政年份:1985
-
负责人:FRITZ H BACH
-
依托单位:
STUDIES OF HLA CLASS II GENES
-
批准号:3134130
-
项目类别:
-
资助金额:$26.72万
-
财政年份:1985
-
负责人:FRITZ H BACH
-
依托单位:
海外基金